Cheng H C, Gleason E M, Nathan B A, Lachmann P J, Woodward J K
J Pharmacol Exp Ther. 1981 Apr;217(1):121-6.
The effect of clonidine on gastric acid secretion was studied in the pylorus ligated stomach (Shay test) and in the perfused stomach of the rat. Clonidine produced biphasic (inhibitory and stimulatory) effects on gastric acid secretion. In the Shay test, clonidine produced only an inhibitory effect on spontaneous gastric acid secretion in a dose-dependent manner (ED50 = 0.042 mg/kg, intraduodenal administration). In the perfused stomach, clonidine in a dose range of 0.625 to 5 mg/kg i.p. slightly increased acid secretion. The secretion, induced by 5 mg/kg of clonidine, was antagonized by cimetidine (10 mg/kg i.p.) but was not affected by phentolamine. Clonidine, 1.25 mg/kg i.p., a dose which had only a slight stimulatory effect, enhanced histamine- and bethanechol-induced secretion. The enhancement of bethanechol-induced secretion was blocked by pretreatment with cimetidine, suggesting histamine H2 receptor stimulation by clonidine. After i.p. (1.25 mg/kg) or intracerebroventricular (i.c.v., 20 and 40 micrograms/kg) administration, clonidine antagonized 2-deoxy-D-glucose-induced acid secretion. Clonidine also inhibited secretion induced by vagal stimulation in anesthetized, vagi-sectioned rats. These results suggest that clonidine had both central and peripheral sites of action. The inhibitory effect on secretion induced by vagal stimulation was blocked by phentolamine (alpha-1 and alpha-2 adrenergic receptor blocker) but not by labetalol (which blocks alpha-1 but not alpha-2 receptors). It is proposed that the inhibitory effect of clonidine is due to its effect on presynaptic alpha-2 adrenergic receptors located on the postganglionic vagal fibers to the stomach. In summary, these data suggest that clonidine inhibited gastric acid secretion by both a central and a peripheral mechanism. As the dose was increased, clonidine also stimulated acid secretion by a stimulation of histamine H2 receptors.
在幽门结扎的大鼠胃( Shay 试验)和大鼠灌流胃中研究了可乐定对胃酸分泌的影响。可乐定对胃酸分泌产生双相(抑制和刺激)作用。在 Shay 试验中,可乐定以剂量依赖性方式对自发性胃酸分泌仅产生抑制作用(十二指肠内给药的 ED50 = 0.042 mg/kg)。在灌流胃中,腹腔注射剂量范围为 0.625 至 5 mg/kg 的可乐定可使胃酸分泌略有增加。5 mg/kg 可乐定诱导的分泌可被西咪替丁(腹腔注射 10 mg/kg)拮抗,但不受酚妥拉明影响。腹腔注射 1.25 mg/kg 的可乐定,该剂量仅产生轻微的刺激作用,可增强组胺和氨甲酰甲胆碱诱导的分泌。氨甲酰甲胆碱诱导的分泌增强可被西咪替丁预处理阻断,提示可乐定刺激组胺 H2 受体。腹腔注射(1.25 mg/kg)或脑室内注射(脑室内,20 和 40 μg/kg)后,可乐定拮抗 2-脱氧-D-葡萄糖诱导的胃酸分泌。可乐定还抑制麻醉的、切断迷走神经的大鼠迷走神经刺激诱导的分泌。这些结果表明可乐定具有中枢和外周作用部位。对迷走神经刺激诱导的分泌的抑制作用可被酚妥拉明(α-1 和 α-2 肾上腺素能受体阻滞剂)阻断,但不被拉贝洛尔(阻断 α-1 但不阻断 α-2 受体)阻断。有人提出可乐定的抑制作用是由于其对位于支配胃的节后迷走神经纤维上的突触前 α-2 肾上腺素能受体的作用。总之,这些数据表明可乐定通过中枢和外周机制抑制胃酸分泌。随着剂量增加,可乐定还通过刺激组胺 H2 受体刺激胃酸分泌。